Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunological Signatures of MASLD and MASH in Patients With Type 1 Diabetes

NCT07927647 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07927647 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Immunological Signatures of MASLD and MASH in Patients With Type 1 Diabetes
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
December 31, 2028
Enrollment
1,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic dysfunction-associated steatohepatitis (mash), metabolic dysfunction-associated steatotic liver disease (masld), type 1 diabetes mellitus (t1d), type 2 diabetes mellitus (t2d)

Arms

As registered; 2 arms.

  • Control arms

    Control arms with data from patients living with type 2 diabetes (T2D) who were previously included in the AngioSafe T2D cohort.

  • Study arm

    Study arm comprising all consecutive adult patients living with type 1 diabetes who attend the day hospital units of the diabetology departments at Lariboisière and Bichat Hospitals (Paris), during which they undergo liver assessment using FibroScan as part of routine clinical care.

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Comparison of circulating immune-cell subset frequencies according to liver status in patients with type 1 diabetes Baseline (single day-hospital visit).

    Frequencies of circulating immune-cell subsets, expressed as percentages of the relevant parent cell population, will be quantified by multiparameter flow cytometry. Measurements will be compared across three liver-status groups defined by FibroScan: no steatosis (CAP \< 250 dB/m and liver stiffness \< 8 kPa), MASLD without elevated liver stiffness (CAP ≥ 250 dB/m and liver stiffness \< 8 kPa), and MASLD with elevated liver stiffness (CAP ≥ 250 dB/m and liver stiffness ≥ 8 kPa).

  • Comparison of circulating immune-cell gene expression profiles according to liver status in patients with type 1 diabetes Baseline (single day-hospital visit)

    Transcriptomic profiles of circulating immune cells will be assessed using gene expression analysis. Differential gene expression between liver-status groups will be evaluated using normalized gene expression measurements and statistical analyses, as specified in the study protocol.

Lead sponsor's other trials

Assistance Publique - Hôpitaux de Paris, most recent start first.

Similar trials

Same condition (Fatty Liver) and phase, most recent start first.